| scholarly article | Q13442814 |
| P2093 | author name string | Andreas A Argyriou | |
| P2860 | cites work | Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer | Q58874370 |
| Chemotherapy-induced peripheral neurotoxicity | Q60750355 | ||
| Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy | Q80349606 | ||
| Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity | Q80704615 | ||
| Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer | Q81242311 | ||
| A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer | Q86521729 | ||
| Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study | Q44304377 | ||
| Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy | Q44545859 | ||
| Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain | Q44892080 | ||
| Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer | Q44951979 | ||
| Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer | Q45091068 | ||
| Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer | Q45166759 | ||
| Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer | Q45735303 | ||
| Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy | Q46726140 | ||
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study | Q46900220 | ||
| Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients | Q50797877 | ||
| Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study | Q50887433 | ||
| Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients | Q50922149 | ||
| Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients | Q53129040 | ||
| Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study | Q58874339 | ||
| Interventions for preventing neuropathy caused by cisplatin and related compounds | Q24236661 | ||
| Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study. | Q30818191 | ||
| Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer | Q33372496 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial | Q34336573 | ||
| Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer | Q34494728 | ||
| Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice | Q35019148 | ||
| Platinum-induced neurotoxicity and preventive strategies: past, present, and future | Q35345734 | ||
| Oxaliplatin in the treatment of colorectal cancer | Q36788436 | ||
| A review on oxaliplatin-induced peripheral nerve damage. | Q37086984 | ||
| Central and peripheral nervous system toxicity of common chemotherapeutic agents. | Q37335100 | ||
| Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies | Q37347237 | ||
| A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen | Q37383249 | ||
| Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. | Q37659699 | ||
| Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). | Q37662241 | ||
| Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. | Q37799782 | ||
| Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics | Q37896345 | ||
| Chemotherapy-induced peripheral neurotoxicity (CIPN): an update | Q37930268 | ||
| Oxaliplatin induced-neuropathy in digestive tumors | Q38136859 | ||
| Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? | Q38280297 | ||
| Glial role in oxaliplatin-induced neuropathic pain | Q39204930 | ||
| Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin | Q39252089 | ||
| Acute oxaliplatin-induced peripheral nerve hyperexcitability | Q39408791 | ||
| Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis. | Q41095276 | ||
| Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? | Q43146147 | ||
| Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? | Q43188321 | ||
| Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. | Q43278321 | ||
| Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy. | Q43279449 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | oxaliplatin | Q422327 |
| neurotoxicity | Q3338704 | ||
| toxic encephalopathy | Q7830379 | ||
| P304 | page(s) | 187-197 | |
| P577 | publication date | 2015-05-29 | |
| P1433 | published in | Toxics | Q27725865 |
| P1476 | title | Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN). | |
| P478 | volume | 3 |
| Q91747390 | Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats |
| Q53074949 | Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer |
| Q49439093 | Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients |
| Q99570047 | Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-induced painful peripheral neuropathy |
| Q55437025 | Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. |
| Q97541497 | The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey |
| Q64998809 | The nucleolus, an ally, and an enemy of cancer cells. |
| Q42361402 | Toxicities of Therapeutic Agents Used in Medicine |
Search more.